TransMedics (TMDX) Cost of Revenue (2018 - 2026)

TransMedics' Cost of Revenue history runs 9 years deep, the most recent figure standing at $72.8 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 31.57% year-over-year to $72.8 million; the TTM figure through Mar 2026 stood at $260.2 million (up 31.47% YoY), while the FY2025 annual figure was $242.7 million, up 35.23% from the prior year.
• Cost of Revenue was $72.8 million for Q1 2026 at TransMedics, up from $67.4 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $72.8 million in Q1 2026 to a low of $3.8 million in Q1 2022.
• Historically, Cost of Revenue has averaged $35.9 million across 5 years, with a median of $36.9 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue jumped 373.89% in 2022, then gained 23.65% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $10.7 million in 2022, then jumped by 211.56% to $33.2 million in 2023, then surged by 49.21% to $49.6 million in 2024, then soared by 35.76% to $67.4 million in 2025, then climbed by 8.05% to $72.8 million in 2026.
• The last three Cost of Revenue figures came in at $72.8 million (Q1 2026), $67.4 million (Q4 2025), and $59.2 million (Q3 2025), per Business Quant data.